• Aptahem signed a non-binding clinical development collaboration LOI with Linköping University professor Folke Sjöberg on Sept. 25, 2026.
• Work targets a patient-study plan for Apta-1, focusing on severely burned patients where infections can progress to sepsis.
• Apta-1 has completed Phase 1 with no signs of serious adverse events; aim is to move toward Phase 2.
• Planning covers patient selection, endpoints, safety follow-up, recruitment feasibility, regulatory preparations, resource needs, financing model.
• Any study start remains subject to separate agreements, funding, necessary approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptahem AB published the original content used to generate this news brief on September 25, 2026, and is solely responsible for the information contained therein.